{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:32:26Z","timestamp":1780641146225,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001661","name":"Ruprecht-Karls-Universit\u00e4t Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The costs, operational barriers, and sensitivity of available tools to confirm a TB diagnosis limit current active case-finding (ACF) efforts for tuberculosis (TB). However, it is not well understood which of these limitations have the greatest epidemiological relevance and might therefore warrant prioritization in confirmatory test development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To explore which features of the confirmatory testing step most influence the impact of ACF, we developed a state-transition model of a one-time, community-based ACF campaign, with a fixed budget of one million United States dollars for screening and confirmatory testing, assuming an adult target population with four times the national prevalence of Uganda. We compared TB diagnoses, mortality, and transmission when conducting ACF with a currently available confirmatory test (mirroring sputum-based Xpert Ultra) versus ACF with an improved confirmatory test, i.e., (1) increased sensitivity (from 69% to 80%), (2) non-sputum specimen type (increasing specimen availability from 93% to 100%), (3) immediate turn-around of test results at the point-of-care (increasing delivery of positive results from 91% to 100%), or (4) reduced costs (from $20 to $10 per confirmatory test).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a simulated target population of 500,000 adults, 8,029 (1.6%; 95% uncertainty range [UR] 6,634-9,380) had TB disease, and 1,136 (789-1,586) were projected to die of TB in the absence of ACF. Assuming current tests, ACF could reach 149,811 (90,834\u2009\u2212\u2009217,928; 30% of the target population) people under the allotted budget, connecting 1,151 (676-1,813) individuals with TB to treatment and averting 135 (64\u2013249) deaths. Higher diagnostic sensitivity most increased the number of people with TB who received treatment as a result of ACF (by 15% [5\u201327%]). However, improvements that could benefit individuals regardless of their sputum bacillary load, such as reduced test costs, achieved larger reductions in mortality (11% [4\u201336%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Due to greater detection of individuals with high bacillary load, making confirmatory tests for community-based TB screening less expensive and more accessible may lead to greater population health benefits than further increasing test sensitivity. Nonetheless, achieving large (&gt;\u200920%) increases in the health impact of ACF will require improvements to components of ACF other than the confirmatory diagnostic test.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11905-3","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:19:01Z","timestamp":1761571141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Importance of confirmatory test characteristics in optimizing community-based screening for tuberculosis: an epidemiological modeling analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Lukas E.","family":"Br\u00fcmmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa S.","family":"Ryckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourya","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Worodria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devasahayam J.","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Theron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Cattamanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M.","family":"Denkinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dowdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"11905_CR1","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva (Switzerland); 2023."},{"issue":"5","key":"11905_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1164\/rccm.201207-1217OC","volume":"187","author":"DW Dowdy","year":"2013","unstructured":"Dowdy DW, Basu S, Andrews JR. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med. 2013;187(5):543\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"11905_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08502-7","volume":"23","author":"MD Fenta","year":"2023","unstructured":"Fenta MD, Ogundijo OA, Warsame AAA, Belay AG. Facilitators and barriers to tuberculosis active case findings in low- and middle-income countries: a systematic review of qualitative research. BMC Infect Dis. 2023;23(1):515.","journal-title":"BMC Infect Dis"},{"key":"11905_CR4","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2: screening. Geneva (Switzerland); 2021."},{"issue":"6","key":"11905_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058195","volume":"12","author":"S Floyd","year":"2022","unstructured":"Floyd S, Klinkenberg E, de Haas P, Kosloff B, Gachie T, Dodd PJ, et al. Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa. BMJ Open. 2022;12(6):e058195.","journal-title":"BMJ Open"},{"issue":"12","key":"11905_CR6","doi-asserted-by":"publisher","first-page":"e1035","DOI":"10.1093\/cid\/ciaa1824","volume":"72","author":"EA Kendall","year":"2021","unstructured":"Kendall EA, Kitonsa PJ, Nalutaaya A, Erisa KC, Mukiibi J, Nakasolya O, et al. The spectrum of tuberculosis disease in an urban Ugandan community and its health facilities. Clin Infect Dis. 2021;72(12):e1035\u201343.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11905_CR7","doi-asserted-by":"publisher","first-page":"e987","DOI":"10.1093\/cid\/ciac492","volume":"76","author":"D Puma","year":"2023","unstructured":"Puma D, Yuen CM, Millones AK, Brooks MB, Jimenez J, Calderon RI, et al. Sensitivity of various case detection algorithms for Community-based tuberculosis screening. Clin Infect Dis. 2023;76(3):e987\u20139.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"11905_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.5588\/ijtld.16.0200","volume":"20","author":"E Hsiang","year":"2016","unstructured":"Hsiang E, Little KM, Haguma P, Hanrahan CF, Katamba A, Cattamanchi A, et al. Higher cost of implementing Xpert((R)) MTB\/RIF in Ugandan peripheral settings: implications for cost-effectiveness. Int J Tuberc Lung Dis. 2016;20(9):1212\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"11905_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1473-3099(17)30691-6","volume":"18","author":"SE Dorman","year":"2018","unstructured":"Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, et al. Xpert MTB\/RIF ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76\u201384.","journal-title":"Lancet Infect Dis"},{"key":"11905_CR10","doi-asserted-by":"publisher","DOI":"10.2471\/B09111","volume-title":"Target product profiles for tuberculosis diagnosis and detection of drug resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Target product profiles for tuberculosis diagnosis and detection of drug resistance. Switzerland: Geneva; 2024."},{"issue":"9","key":"11905_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1086\/591974","volume":"47","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Kik SV, Kalisvaart NA, Sebek MM, Verver S, Boeree MJ, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis. 2008;47(9):1135\u201342.","journal-title":"Clin Infect Dis"},{"issue":"52","key":"11905_CR12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2211045119","volume":"119","author":"TS Ryckman","year":"2022","unstructured":"Ryckman TS, Dowdy DW, Kendall EA. Infectious and clinical tuberculosis trajectories: bayesian modeling with case finding implications. Proc Natl Acad Sci U S A. 2022;119(52):e2211045119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11905_CR13","doi-asserted-by":"publisher","unstructured":"Emery JC, Dodd PJ, Banu S, Frascella B, Garden FL, Horton KC, et al. Estimating the contribution of subclinical tuberculosis disease to transmission: an individual patient data analysis from prevalence surveys.\u00a0Elife. 2023;12:e82469. https:\/\/doi.org\/10.7554\/eLife.82469.","DOI":"10.7554\/eLife.82469"},{"issue":"5","key":"11905_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.5588\/ijtldopen.23.0624","volume":"1","author":"NJ Henry","year":"2024","unstructured":"Henry NJ, Zawedde-Muyanja S, Majwala RK, Turyahabwe S, Barnabas RV, Reiner RC Jr., et al. Mapping TB incidence across districts in Uganda to inform health program activities. IJTLD Open. 2024;1(5):223\u20139.","journal-title":"IJTLD Open"},{"key":"11905_CR15","unstructured":"The Republic of Uganda. The Uganda National Tuberculosis Prevalence Survey, 2014\u20132015 Survey Report.\u00a0Kampala: 2017."},{"key":"11905_CR16","unstructured":"The Republic of Uganda. Uganda population-based HIV impact assessment.\u00a0Kampala: 2022."},{"issue":"1","key":"11905_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5588\/ijtld.13.0129","volume":"18","author":"JN Sekandi","year":"2014","unstructured":"Sekandi JN, List J, Luzze H, Yin XP, Dobbin K, Corso PS, et al. Yield of undetected tuberculosis and human immunodeficiency virus coinfection from active case finding in urban Uganda. Int J Tuberc Lung Dis. 2014;18(1):13\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11905_CR18","unstructured":"World Health Organization. Global tuberculosis report 2014.\u00a0Geneva (Switzerland); 2014."},{"key":"11905_CR19","unstructured":"Republic of South Africa National Department of Health. The first National TB prevalence Survey - South Africa 2018. Pretoria (South Africa); 2021."},{"issue":"9","key":"11905_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004278","volume":"20","author":"E Klinkenberg","year":"2023","unstructured":"Klinkenberg E, Floyd S, Shanaube K, Mureithi L, Gachie T, de Haas P, et al. Tuberculosis prevalence after 4 years of population-wide systematic TB symptom screening and universal testing and treatment for HIV in the HPTN 071 (PopART) community-randomised trial in Zambia and South africa: a cross-sectional survey (TREATS). PLoS Med. 2023;20(9):e1004278.","journal-title":"PLoS Med"},{"issue":"11","key":"11905_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.5588\/ijtldopen.24.0319","volume":"1","author":"PJ Kitonsa","year":"2024","unstructured":"Kitonsa PJ, Sung J, Isooba D, Birabwa S, Naluyima I, Kakeeto J, et al. Quantifying sputum production success during community-based screening for TB. IJTLD Open. 2024;1(11):522\u20134.","journal-title":"IJTLD Open"},{"issue":"8","key":"11905_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044867","volume":"11","author":"P Lungu","year":"2021","unstructured":"Lungu P, Kerkhoff AD, Kasapo CC, Mzyece J, Nyimbili S, Chimzizi R, et al. Tuberculosis care cascade in Zambia - identifying the gaps in order to improve outcomes: a population-based analysis. BMJ Open. 2021;11(8):e044867.","journal-title":"BMJ Open"},{"key":"11905_CR23","unstructured":"World Health Organization. Tuberculosis data, CVS files to download. Geneva (Switzerland). 2023. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/data.\u00a0Accessed 23\u00a0March 2023."},{"issue":"1","key":"11905_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002202","volume":"14","author":"EA Kendall","year":"2017","unstructured":"Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, et al. Priority-setting for novel drug regimens to treat tuberculosis: an epidemiologic model. PLoS Med. 2017;14(1):e1002202.","journal-title":"PLoS Med"},{"issue":"12","key":"11905_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145796","volume":"10","author":"GM Knight","year":"2015","unstructured":"Knight GM, Gomez GB, Dodd PJ, Dowdy D, Zwerling A, Wells WA, et al. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. PLoS ONE. 2015;10(12):e0145796.","journal-title":"PLoS ONE"},{"issue":"7","key":"11905_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200150","volume":"13","author":"B Velayutham","year":"2018","unstructured":"Velayutham B, Chadha VK, Singla N, Narang P, Gangadhar Rao V, Nair S, et al. Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the revised National tuberculosis control Programme, India: a multi-centric prospective study. PLoS ONE. 2018;13(7):e0200150.","journal-title":"PLoS ONE"},{"issue":"3","key":"11905_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5588\/ijtld.22.0567","volume":"27","author":"Y Baik","year":"2023","unstructured":"Baik Y, Nakasolya O, Isooba D, Mukiibi J, Kitonsa PJ, Erisa KC, et al. Cost to perform door-to-door universal sputum screening for TB in a high-burden community. Int J Tuberc Lung Dis. 2023;27(3):195\u2013201.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11905_CR28","unstructured":"Stop TB, Partnership. Artificial intelligence-powered computer-aided (CAD) software. 2025. Available from: https:\/\/www.stoptb.org\/introducing-new-tools-project\/artificial-intelligence-powered-computer-aided-detection-cad-software.\u00a0Accessed 4 Aug 2025."},{"key":"11905_CR29","unstructured":"Stop TB. Partnership. Diagnostics, medical devices & other health products catalog. 2025. Available from: https:\/\/www.stoptb.org\/sites\/default\/files\/documents\/2025.07.07%20GDF_Diag%20and%20MD_catalog.pdf.\u00a0Accessed 4 Aug 2025."},{"key":"11905_CR30","unstructured":"Jiji Vehicels. Toyota Buses & Microbuses in Uganda. 2025. Available from: https:\/\/jiji.ug\/buses\/toyota.\u00a0Accessed 4 Aug 2025."},{"key":"11905_CR31","unstructured":"Global Petrol Prices. Uganda Diesel prices, litre, 04-Aug-2025. 2025. Available from: https:\/\/www.globalpetrolprices.com\/Uganda\/diesel_prices\/. Accessed 4 Aug 2025."},{"key":"11905_CR32","unstructured":"The Global Fund. Global Fund, stop TB partnership and USAID announce new collaboration with Danaher to reduce price and. Increase Access to Cepheid\u2019s TB Test.\u00a0Geneva (Switzerland); 2023."},{"issue":"2","key":"11905_CR33","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2214-109X(22)00509-5","volume":"11","author":"RR Thompson","year":"2023","unstructured":"Thompson RR, Nalugwa T, Oyuku D, Tucker A, Nantale M, Nakaweesa A, et al. Multicomponent strategy with decentralised molecular testing for tuberculosis in uganda: a cost and cost-effectiveness analysis. Lancet Glob Health. 2023;11(2):e278\u201386.","journal-title":"Lancet Glob Health"},{"key":"11905_CR34","unstructured":"World Bank. GDP deflator (base year varies by country) - United States. 2025. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.KD.ZG?locations=US. Accessed on: 4\u00a0August 2025."},{"key":"11905_CR35","unstructured":"World Health Organization. High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting.\u00a0Geneva (Switzerland); 2014."},{"issue":"1","key":"11905_CR36","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2214-109X(23)00469-2","volume":"12","author":"EC Church","year":"2024","unstructured":"Church EC, Steingart KR, Cangelosi GA, Ruhwald M, Kohli M, Shapiro AE. Oral swabs with a rapid molecular diagnostic test for pulmonary tuberculosis in adults and children: a systematic review. Lancet Glob Health. 2024;12(1):e45\u201354.","journal-title":"Lancet Glob Health"},{"key":"11905_CR37","doi-asserted-by":"crossref","unstructured":"Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T et al.\u00a0New manual quantitative polymerase chain reaction assay validated on tongue swabs collected and processed in Uganda shows sensitivity that rivals sputum-based molecular tuberculosis diagnostics. Clin Infect Dis. 2024;78(5):1313\u201320.","DOI":"10.1093\/cid\/ciae041"},{"key":"11905_CR38","doi-asserted-by":"crossref","unstructured":"Steadman A, Kumar KM, Asege L, Kato-Maeda M, Mukwatamundu J, Shah K et al. Diagnostic accuracy of swab-based molecular tests for tuberculosis using novel near point-of-care platforms: A multi-country evaluation. Preprint [medXriv]. 2025.","DOI":"10.2139\/ssrn.5273912"},{"issue":"1","key":"11905_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02128-9","volume":"19","author":"CC Ku","year":"2021","unstructured":"Ku CC, MacPherson P, Khundi M, Nzawa Soko RH, Feasey HRA, Nliwasa M, et al. Durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease with a bayesian analysis of prevalence survey and notification data. BMC Med. 2021;19(1):298.","journal-title":"BMC Med"},{"key":"11905_CR40","unstructured":"UNAIDS. AIDSinfo \u2013 Global data on HIV epidemic and response. Geneva (Switzerland). 2023. Available from: https:\/\/aidsinfo.unaids.org.\u00a0Accessed 23\u00a0March 2023."},{"key":"11905_CR41","unstructured":"United Nations. Crude death rate per country. Manhattan (NY, United States). 2023. Available from: https:\/\/data.un.org\/Data.aspx?d=PopDiv&f=variableID%3A65. Accessed on: 23 March 2023."},{"key":"11905_CR42","doi-asserted-by":"crossref","unstructured":"Akessa GM, Tadesse M, Abeb G. Survival Analysis of Loss to Follow-Up Treatment among Tuberculosis Patients at Jimma University Specialized Hospital, Jimma, Southwest Ethiopia.\u00a0International Journal of Statistical Mechanics. 2015;1:923025.","DOI":"10.1155\/2015\/923025"},{"issue":"8","key":"11905_CR43","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1093\/cid\/ciy665","volume":"68","author":"GJ Fox","year":"2019","unstructured":"Fox GJ, Nguyen VN, Dinh NS, Nghiem LPH, Le TNA, Nguyen TA, et al. Post-treatment mortality among patients with tuberculosis: a prospective cohort study of 10 964 patients in Vietnam. Clin Infect Dis. 2019;68(8):1359\u201366.","journal-title":"Clin Infect Dis"},{"key":"11905_CR44","unstructured":"AIDS Healthcare Foundation. The fifth South African national HIV prevalence, incidence, behaviour and communication survey.\u00a0Los Angeles, CA (United States); 2018."},{"key":"11905_CR45","unstructured":"Ministry of Health & Family Welfare - Government of India. India Tuberculosis Report.\u00a0New Delhi (India); 2022."},{"issue":"6","key":"11905_CR46","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/inthealth\/ihaa105","volume":"13","author":"M Muniyandi","year":"2021","unstructured":"Muniyandi M, Lavanya J, Karikalan N, Saravanan B, Senthil S, Selvaraju S, et al. Estimating TB diagnostic costs incurred under the National tuberculosis elimination programme: a costing study from Tamil Nadu, South India. Int Health. 2021;13(6):536\u201344.","journal-title":"Int Health"},{"key":"11905_CR47","volume-title":"India HIV estimates 2021: fact sheet","author":"National AIDS Control Organization & ICMR-National Institute of Medical Statistics","year":"2022","unstructured":"National AIDS Control Organization & ICMR-National Institute of Medical Statistics. India HIV estimates 2021: fact sheet. New Delhi, India: Ministry of Health and Family Welfare, Government of India; 2022."},{"issue":"6","key":"11905_CR48","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2214-109X(19)30164-0","volume":"7","author":"A Pooran","year":"2019","unstructured":"Pooran A, Theron G, Zijenah L, Chanda D, Clowes P, Mwenge L, et al. Point of care Xpert MTB\/RIF versus smear microscopy for tuberculosis diagnosis in Southern African primary care clinics: a multicentre economic evaluation. Lancet Glob Health. 2019;7(6):e798\u2013807.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"11905_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/lungindia.lungindia_181_19","volume":"37","author":"R Sathiyamoorthy","year":"2020","unstructured":"Sathiyamoorthy R, Kalaivani M, Aggarwal P, Gupta SK. Prevalence of pulmonary tuberculosis in India: a systematic review and meta-analysis. Lung India. 2020;37(1):45\u201352.","journal-title":"Lung India"},{"key":"11905_CR50","unstructured":"Cambodia Ministry of Health. Report of the second National tuberculosis prevalence survey, 2011.\u00a0Phnom Penh (Cambodia); 2012."},{"key":"11905_CR51","volume-title":"First National TB prevalence survey 2012, Nigeria","author":"Federal Republic of Nigeria","year":"2012","unstructured":"Federal Republic of Nigeria. First National TB prevalence survey 2012, Nigeria. Nigeria: Abuja; 2012."},{"issue":"12","key":"11905_CR52","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.5588\/ijtld.21.0129","volume":"25","author":"A Kairu","year":"2021","unstructured":"Kairu A, Orangi S, Oyando R, Kabia E, Nguhiu P, Ong Ang OJ, et al. Cost of TB services in healthcare facilities in Kenya (3). Int J Tuberc Lung Dis. 2021;25(12):1028\u201334.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"11905_CR53","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5588\/pha.18.0098","volume":"9","author":"SM Machekera","year":"2019","unstructured":"Machekera SM, Wilkinson E, Hinderaker SG, Mabhala M, Zishiri C, Ncube RT, et al. A comparison of the yield and relative cost of active tuberculosis case-finding algorithms in Zimbabwe. Public Health Action. 2019;9(2):63\u20138.","journal-title":"Public Health Action"},{"issue":"8","key":"11905_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001281","volume":"9","author":"K Kranzer","year":"2012","unstructured":"Kranzer K, Lawn SD, Meyer-Rath G, Vassall A, Raditlhalo E, Govindasamy D, et al. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in cape Town, South africa: a cross-sectional study. PLoS Med. 2012;9(8):e1001281.","journal-title":"PLoS Med"},{"issue":"8","key":"11905_CR55","first-page":"936","volume":"12","author":"E Botha","year":"2008","unstructured":"Botha E, den Boon S, Lawrence KA, Reuter H, Verver S, Lombard CJ, et al. From suspect to patient: tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis. 2008;12(8):936\u201341.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11905_CR56","unstructured":"World Health Organization. The End TB strategy.\u00a0Geneva(Switzerland); 2015."},{"key":"11905_CR57","doi-asserted-by":"crossref","unstructured":"Garcia LS, Costa AG, Araujo-Pereira M, Spener-Gomes R, Aguiar AF, Souza AB et al. The Xpert(R) MTB\/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort.\u00a0Clin Infect Dis. 2024;ciad794.","DOI":"10.1093\/cid\/ciad794"},{"issue":"4","key":"11905_CR58","doi-asserted-by":"publisher","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","volume":"6","author":"EW Tiemersma","year":"2011","unstructured":"Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE. 2011;6(4):e17601.","journal-title":"PLoS ONE"},{"issue":"7","key":"11905_CR59","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1016\/S2214-109X(24)00178-5","volume":"12","author":"A Nooy","year":"2024","unstructured":"Nooy A, Ockhuisen T, Korobitsyn A, Khan SA, Ruhwald M, Ismail N, et al. Trade-offs between clinical performance and test accessibility in tuberculosis diagnosis: a multi-country modelling approach for target product profile development. Lancet Glob Health. 2024;12(7):e1139\u201348.","journal-title":"Lancet Glob Health"},{"issue":"8","key":"11905_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043307","volume":"7","author":"SE Dorman","year":"2012","unstructured":"Dorman SE, Chihota VN, Lewis JJ, Shah M, Clark D, Grant AD, et al. Performance characteristics of the cepheid Xpert MTB\/RIF test in a tuberculosis prevalence survey. PLoS ONE. 2012;7(8):e43307.","journal-title":"PLoS ONE"},{"issue":"6","key":"11905_CR61","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1513\/AnnalsATS.202308-752OC","volume":"21","author":"SR Cox","year":"2024","unstructured":"Cox SR, Erisa KC, Kitonsa PJ, Nalutaaya A, Nantale M, Kayondo F, et al. Accuracy of C-reactive protein for tuberculosis detection in general-population screening and ambulatory-care triage in Uganda. Ann Am Thorac Soc. 2024;21(6):875\u201383.","journal-title":"Ann Am Thorac Soc"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11905-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T13:19:19Z","timestamp":1761571159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11905-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11905"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11905-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.M. D. reports research grants from the US NIH, German Ministry of Education and Research, German Alliance for Global Health research, USAID, FIND, German Center for Infection Research, UNAIDS, World Health Organization (WHO). C. M. D. also reports a role as academic editor for PLoS Med and on technical advisory group Tuberculosis diagnostics for WHO. A. C. reports grants to institution from U.S. NIH, Global Health Labs, Stop TB Partnership, and Bill and Melinda Gates Foundation and unpaid participation on an Advisory Board for EDCTP-funded TB diagnostic trial. G. T. reports grants from the EDCTP2 program supported by the EU (RIA2018D-2509, PreFIT; RIA2018D-2493, SeroSelectTB; RIA2020I-3305, CAGE-TB) and the National Institutes of Health (D43TW010350; U01AI152087; U54EB027049; R01AI136894). F.M.M. reports a research grant from the Bill and Melinda Gates Foundation. All other authors report no potential conflicts.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1415"}}